Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22-Dual-STAR-T Cells in Relapsed/Refractory B-ALL
NCT04508842Phase 1Terminated
- Sponsor
- Lu Daopei Hospital
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22-dual-STAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Lu Daopei Hospital. Primary endpoint: Percentage of participants with adverse events at 12 months. Started Oct 2020; status: terminated.
02
Drugs
CD19/CD22-dual-STAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04508842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508842.